Express News | Huaxia Eye Hospital Says Actual Controller, Chairman SU Qingcan Released From Detention and Placed Under Residential Surveillance
Huaxia Eye Hospital (301267.SZ) has repurchased 0.62% of the shares.
Huaxia Eye Medicine(301267.SZ) announced that by May 31, 2024, it repurchased a total of 5,225,140 shares through the share repurchase securities account in the concentrated bidding trading method, accounting for 0.62% of the company's current total share capital. The highest fill price was 30.93 yuan/share, and the lowest fill price was 25.01 yuan/share. The total accumulated transaction amount was 150,985,900 yuan (excluding transaction fees).
Huaxia Eye Hospital GroupLtd (SZSE:301267) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' It's only natural to co
Huaxia Ophthalmology (301267.SZ): Net profit of 156 million yuan in the first quarter increased 3.75% year on year
Gelonghui, April 26 | Huaxia Ophthalmology (301267.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 978 million yuan, up 5.09% year on year; net profit attributable to shareholders of listed companies was 156 million yuan, up 3.75% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 157 million yuan, up 6.89% year on year; basic earnings per share were 0.19 yuan.
Huaxia Ophthalmology (301267.SZ) has repurchased a total of 5.2251 million shares at a cost of 151 million yuan
Huaxia Ophthalmology (301267.SZ) announced that as of February 29, 2024, the company is using centralized bidding transactions...
Returns At Huaxia Eye Hospital GroupLtd (SZSE:301267) Appear To Be Weighed Down
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Typically, we'll want to notice a trend of growing return on capi
Huaxia Ophthalmology (301267.SZ) has repurchased a total of 3.788 million shares at a cost of 111 million yuan
Huaxia Ophthalmology (301267.SZ) announced that as of January 31, 2024, the company is using centralized bidding transactions...
Huaxia Ophthalmology (301267.SZ): We have established long-term and stable cooperative relationships with major ophthalmic medical device manufacturers at home and abroad
Gelonghui January 31 丨 An investor asked Huaxia Ophthalmology (301267.SZ) on the investor interactive platform, “What ophthalmic medical device products has the company laid out?” The company replied that the company has established long-term and stable cooperative relationships with major ophthalmic medical device manufacturers at home and abroad, and has actively introduced cutting-edge international ophthalmology diagnosis and treatment technologies and products to provide comprehensive, diverse and personalized diagnosis and treatment services for patients with eye diseases.
These 4 Measures Indicate That Huaxia Eye Hospital GroupLtd (SZSE:301267) Is Using Debt Safely
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' It's only natural to co
Huaxia Ophthalmology (301267.SZ): Initial repurchase of 687,700 shares involving 20037,800 yuan
Gelonghui, January 22丨Huaxia Ophthalmology (301267.SZ) announced that on January 22, 2024, for the first time, the company repurchased 687,700 shares of the company's shares through a dedicated securities account, accounting for 0.08% of the company's current total share capital. The highest transaction price was 29.70 yuan/share, the minimum transaction price was 28.57 yuan/share, and the total amount paid was 200377.89 million yuan (not including transaction fees).
Huaxia Ophthalmology (301267.SZ): Under the two-wheel drive of “comprehensive eye diseases+consumer medicine”, we strive to achieve the annual performance growth target of 30% or more
Gelonghui, January 16 | Huaxia Ophthalmology (301267.SZ) said on the interactive platform that as a leading ophthalmology chain group in China, the company has outstanding clinical diagnosis and treatment capabilities and large-scale hospital chain management capabilities, and has a certain first-mover advantage and scale effect, leading the industry in various dimensions such as annual number of patients, ophthalmology surgery volume, and revenue; the company is centered on core hospitals with strong diagnosis and treatment capabilities to promote the continuous improvement of the Group's general diagnosis and treatment service system, hospital management and discipline construction; the company has brought together a large number of top experts in the industry to continue to build Department A highland of talent development and diagnosis and treatment technology
Huaxia Ophthalmology (301267.SZ): Plans to spend 150 million yuan to 250 million yuan to buy back the company's shares
Gelonghui, January 8 | Huaxia Ophthalmology (301267.SZ) announced that the company plans to use its own funds to repurchase some of the company's shares through centralized bidding transactions to implement employee stock ownership plans or equity incentives. The total repurchase capital is not less than 150 million yuan and no more than 250 million yuan (all including capital). The repurchase price range does not exceed RMB 50.93 per share. Based on the upper limit of the total repurchase capital of 250 million yuan and the upper limit of the repurchase price of 50.93 yuan/share, the estimated number of shares to be repurchased is approximately 49,086.98 million shares, accounting for about 0.58% of the company's current total share capital; according to the lower limit of the total repurchase amount 1
An Intrinsic Calculation For Huaxia Eye Hospital Group Co.,Ltd. (SZSE:301267) Suggests It's 37% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Huaxia Eye Hospital GroupLtd fair value estimate is CN¥52.74 Current share price of CN¥33.47 suggests Huaxia Eye Hospital GroupLtd is potenti
Huaxia Ophthalmology (301267.SZ): In the future, Nanshan Hospital will be built as an international ophthalmology center
Glonghui, December 14|Huaxia Ophthalmology (301267.SZ) disclosed an investor relations activity record sheet showing that in order to meet the ever-expanding ophthalmology needs, Shenzhen Huaxia built a new Nanshan Hospital on the basis of Futian Hospital this year, which will meet the needs of residents in different districts seeking medical treatment nearby in the future. In the future, the Nanshan Hospital will be built as an international ophthalmology center. Through the introduction of foreign ophthalmologists and cooperation with domestic and foreign commercial insurance institutions, it will provide international high-quality ophthalmology services to patients in the Shenzhen region (including people from overseas). In addition, we will also rely on the two major hospitals to lay out dozens of optometry centers through cooperation with
Huaxia Ophthalmology (301267.SZ): In the future, construction and mergers and acquisitions of ophthalmology hospitals will be carried out simultaneously
Glonghui, December 14|Huaxia Ophthalmology (301267.SZ) disclosed a record list of investor relations activities, showing that in the future, construction and mergers of ophthalmology hospitals will be built simultaneously. If there is an appropriate merger and acquisition target to enter the market, priority will be given to mergers and acquisitions; if there is no suitable target, we will enter the market by building a new one. Relying on Huaxia Ophthalmology Group's business advantages, the merger and acquisition method can quickly implement resource input and advantage empowerment in academia, talent, capital, procurement, etc. on the hospital's existing basis, helping the hospital improve operating efficiency and release profits more quickly. We hope to “double” through endogenous growth and external mergers and acquisitions
Su Qingcan, the actual controller of Huaxia Ophthalmology (301267.SZ), was detained for personal reasons
Huaxia Ophthalmology (301267.SZ) issued an announcement. The company received a notice on December 6, 2023. The company actually...
Returns On Capital At Huaxia Eye Hospital GroupLtd (SZSE:301267) Have Hit The Brakes
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One common approach is to try and find a company with returns on capital employed (RO
Huaxia Ophthalmology (301267. SZ): The ban on 239 million restricted shares will be lifted on November 7
On November 1, Huaxia Ophthalmology (301267.SZ) announced an indicative announcement on the lifting of some of the restrictions on sale and listing of issued shares before the initial public offering. The number of shareholders applying to lift the share sale restrictions is 11, and the number of shares lifted is 239 million shares, accounting for 28.4321% of the company's total share capital. The sales restriction period is 12 months from the date the company's initial public offering of shares and listing. The date on which the sale restrictions have been lifted can be listed for circulation is November 7, 2023 (Tuesday).
[Instant Analysis of BT Financial Report] Huaxia Ophthalmology 2023 Third Quarter Report: Operating income and net profit both increased, and the field of ophthalmology and medical services continued to gain strength
Announcement time of this financial report: 2023-10-24 18:23:01 Huaxia Eye Hospital Group Co., Ltd. (stock code: 301267) is a leading large-scale ophthalmology medical chain group in China. It mainly provides ophthalmic medical services, including diagnosis and treatment of eye diseases, and prevention and intervention for eye diseases and myopia. The company has opened 57 ophthalmology specialist hospitals and 52 optometry centers nationwide, covering 49 cities in 18 provinces and municipalities. The company's core values are responsibility, care, innovation and win-win. We are committed to providing high-quality, professional and safe ophthalmology treatment for patients
Could The Market Be Wrong About Huaxia Eye Hospital Group Co.,Ltd. (SZSE:301267) Given Its Attractive Financial Prospects?
It is hard to get excited after looking at Huaxia Eye Hospital GroupLtd's (SZSE:301267) recent performance, when its stock has declined 8.8% over the past week. However, a closer look at its sound f
No Data